{"nctId":"NCT02911857","briefTitle":"An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes","startDateStruct":{"date":"2016-10-03","type":"ACTUAL"},"conditions":["Periodic Fevers Syndrome"],"count":4,"armGroups":[{"label":"Canakinumab (ACZ885)","type":"EXPERIMENTAL","interventionNames":["Biological: Canakinumab (AIN457)"]}],"interventions":[{"name":"Canakinumab (AIN457)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Completed Epoch 4 of the CACZ885N2301 study in Japan before the approval of canakinumab in Japan\n* Written informed consent. Parent or legal guardian's written informed consent and child's assent, if appropriate, are required before any assessment is performed for patients \\< 20 years of age\n\nExclusion Criteria:\n\n* Any conditions or significant medical problems in which the investigator judges the patient should not enter this extension study","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Non-serious Adverse Events, Serious Adverse Events and Deaths","description":"Participants were monitored for safety throughout the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":2},"commonTop":["NASOPHARYNGITIS"]}}}